Caption Management’s Summit Therapeutics SMMT Stock Holding History

Caption Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.76M	Buy	326,600 +96,600	+42%	+$1.71M	0.02%	597
2026 Q1	$4.36M	Sell	230,000 -10,000	-4%	-$162K	0.03%	570
2025 Q4	$4.2M	Buy	240,000 +34,500	+17%	+$649K	0.03%	573
2025 Q3	$4.25M	Buy	205,500 +42,000	+26%	+$1.02M	0.03%	555
2025 Q2	$3.48M	Buy	163,500 +153,500	+1,535%	+$3.5M	0.04%	521
2025 Q1	$193K	Buy	+10,000	New	+$201K	﹤0.01%	1280
2024 Q3	–	Sell	-499,100	Closed	-$3.89M	–	1575
2024 Q2	$3.89M	Buy	+499,100	New	+$2.7M	0.06%	324

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Caption Management's SMMT Position: Q2 2026 in Review

Caption Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 100,000 shares worth $1.46M. The stake represents 0.01% of the portfolio and ranks #1004 among its holdings. This is a return to the name: Caption Management previously reported a position in SMMT as recently as Q3 2025.

Caption Management first reported a position in SMMT in Q2 2025 and has held it in 3 quarters since. The position peaked at $5.69M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Caption Management held 100,000 shares of Summit Therapeutics worth $1.46M as of Q2 2026.
Summit Therapeutics was a new Caption Management position in Q2 2026.
Summit Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #1004 holding.
Caption Management first reported a position in Summit Therapeutics in Q2 2025 and has held it in 3 quarters since.
Caption Management's Summit Therapeutics position peaked at $5.69M in Q2 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.